Zoetis could climb 25%, Barron's says Zoetis (ZTS) isn't subject to the same patent expiration cliff as Pfizer (PFE) and earnings should rise 13% over the next few years, Barron's says in its "Weekday Trader" column. Shares could climb 25%, the paper adds. Reference Link
Zoetis receives conditional license from USDA Zoetis announced that the U.S. Department of Agriculture has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic, an antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. The USDA has communicated that all biological products for canine atopic dermatitis will be considered for conditional licensure only at this time. Zoetis said it is working with the USDA to obtain full licensure.